Allergen-Specific Immunotherapy Mechanisms and Clinical Applications

Allergen-specific immunotherapy (AIT) represents the only disease‐modifying treatment for IgE‐mediated allergic conditions, aiming to reprogramme the immune system from a sensitised state towards durable tolerance. The clinical protocol administers gradually increasing doses of the culprit allergen by subcutaneous or sublingual routes, combining early desensitisation of mast cells and basophils with long‐term modulation of adaptive immunity. Central to effective AIT is the induction of regulatory T‐cell subsets that secrete immunosuppressive cytokines, particularly interleukin-10 and transforming growth factor-β, which inhibit Th2-driven inflammation and reduce tissue eosinophilia. Concurrently, a shift in antibody isotypes occurs with diminished allergen‐specific IgE and augmented production of blocking IgG4, which competes with IgE for allergen binding and engages inhibitory Fcγ receptors on effector cells. Advances in molecular allergology have refined vaccine preparations, while adjuvants and epitope‐based peptide formulations aim to enhance safety and shorten treatment courses. Clinical applications span respiratory allergies, insect venom hypersensitivity and emerging food allergy protocols, with growing interest in preventive vaccination strategies for high‐risk cohorts. Overall, AIT exemplifies a precision medicine approach, harnessing immune tolerance mechanisms to deliver long-lasting relief and arrest the progression of allergic disease.

Research from Nature Portfolio

A multilayer‐omics study of insect‐venom AIT initiation has revealed very‐early immunological switches that underpin durable tolerance. High‐resolution single‐cell analyses identified an immediate surge of late-transitional, IL-10-producing B-cell subsets within 8–24 hours of treatment onset, accompanied by transient IL-6 signalling in Th2 lymphocytes without systemic inflammation. Restoration of homeostatic balance between serum IL-6 and classical monocytes by day 7 further characterises the molecular choreography that secures long‐term remission of venom allergy.

Monoclonal IgG antibodies engineered to target the major cat allergen Fel d 1 have demonstrated that simply raising the blocking IgG/IgE ratio can reverse clinical symptoms. In both murine models and cat‐allergic humans, a single dose of high‐affinity IgG reduced nasal provocation responses to levels comparable with multi‐year conventional AIT, revealing that tailored passive immunisation may offer an accelerated route to symptomatic control.

Allergen-Specific Immunotherapy Mechanisms and Clinical Applications publication trend

The graph below shows the total number of articles in allergen-specific immunotherapy mechanisms and clinical applications across all publications each year (not limited to Nature Index journals).

Technical terms

Allergen-Specific Immunotherapy (AIT): A treatment that administers controlled doses of an allergen to induce long-term immune tolerance.

Regulatory T cell (Treg): A subset of T lymphocytes that suppress immune responses and maintain peripheral tolerance.

Type 1 regulatory T cell (Tr1): An inducible Treg subset characterised by high IL-10 production and suppression of effector responses.

Immunoglobulin E (IgE): The antibody isotype that binds high-affinity Fcε receptors on mast cells and basophils, triggering allergic reactions.

Immunoglobulin G4 (IgG4): A non-inflammatory IgG subclass that competes with IgE for allergen and engages inhibitory Fcγ receptors.

Adjuvant: A compound co-administered with antigen to enhance the magnitude and quality of the immune response.

References

1. Multiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy: an observational study. Nature Communications (2024).
2. Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement. Nature Communications (2018).
3. IgE versus IgG and IgA: Differential roles of allergen‐specific antibodies in sensitization, tolerization, and treatment of allergies. Immunological Reviews (2024).
4. Direct exposure to CpG and specific antigens mitigate airway allergy through modulating dendritic cell properties. Biomedicine & Pharmacotherapy (2024).
5. Past, present, and future of allergen immunotherapy vaccines. Allergy (2020).
6. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organization Journal (2015).